| NCT ID | NCT02783300 |
| Title | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | GlaxoSmithKline |
| Indications |
triple-receptor negative breast cancer ureter transitional cell carcinoma renal pelvis transitional cell carcinoma |
| Therapies | |
| Age Groups: | senior adult |